Genoa Pharma raises $62 mln
Genoa Pharmaceuticals Inc said May 15 that it completed a $62 million Series A round of financing led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners. Also participating were Novo AS, RiverVest Venture Partners, and TPG Biotech. Genoa said it named A. Bruce Montgomery, M.D., its CEO, while Mark Surber, Ph.D., the company’s founder and investor, was named chief scientific officer. Genoa, of Seattle, is a biopharmaceutical company focused on developing improved therapies for idiopathic pulmonary fibrosis.
15 May 2017•3 mins read
